Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Authors
Category Primary study
Conference67th American Society of Hematology Annual Meeting, ASH 2025
Year 2025
This article has no abstract
Epistemonikos ID: b44b5398f81e86cc968e1078bd05758ab1aff966
First added on: Jun 15, 2026